Scholarlink

<p>Cenobamate is an antiseizure medication approved in 2021 as add-on therapy for adults with uncontrolled focal seizures. Early trials showed unusually high seizure freedom rates and a favourable tolerability profile, suggesting that cenobamate may represent an important therapeutic advance in the management of focal and other epilepsies. Here, we highlight the latest data from post hoc analyses and clinical studies suggesting that cenobamate is effective across all focal seizure types. It maintains efficacy and safety over the long term, allowing people to reduce their concomitant medications without compromising seizure control. While head-to-head studies are not available, these data, alongside indirect comparisons with other antiseizure medications, support cenobamate as a potentially important advance in the treatment of focal epilepsy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cenobamate: An Appraisal Five Years On

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Eugen Trinka,
  • John Paul Leach,
  • Josemir W. Sander

摘要

Cenobamate is an antiseizure medication approved in 2021 as add-on therapy for adults with uncontrolled focal seizures. Early trials showed unusually high seizure freedom rates and a favourable tolerability profile, suggesting that cenobamate may represent an important therapeutic advance in the management of focal and other epilepsies. Here, we highlight the latest data from post hoc analyses and clinical studies suggesting that cenobamate is effective across all focal seizure types. It maintains efficacy and safety over the long term, allowing people to reduce their concomitant medications without compromising seizure control. While head-to-head studies are not available, these data, alongside indirect comparisons with other antiseizure medications, support cenobamate as a potentially important advance in the treatment of focal epilepsy.